Oakwell Private Wealth Management LLC Purchases 904 Shares of Novo Nordisk A/S (NYSE:NVO)

Oakwell Private Wealth Management LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 12.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,163 shares of the company’s stock after acquiring an additional 904 shares during the period. Oakwell Private Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $702,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NVO. Impact Investors Inc bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $430,000. Cutter & CO Brokerage Inc. raised its position in Novo Nordisk A/S by 2.9% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 290,101 shares of the company’s stock valued at $24,954,000 after purchasing an additional 8,306 shares during the period. Lake Street Advisors Group LLC boosted its holdings in shares of Novo Nordisk A/S by 5.5% in the 4th quarter. Lake Street Advisors Group LLC now owns 15,470 shares of the company’s stock worth $1,331,000 after purchasing an additional 811 shares during the period. Cavalier Investments LLC increased its position in shares of Novo Nordisk A/S by 4.3% during the 4th quarter. Cavalier Investments LLC now owns 23,429 shares of the company’s stock valued at $2,015,000 after purchasing an additional 960 shares during the last quarter. Finally, Edge Capital Group LLC raised its holdings in Novo Nordisk A/S by 1.1% during the 4th quarter. Edge Capital Group LLC now owns 58,465 shares of the company’s stock valued at $5,029,000 after buying an additional 635 shares during the period. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Up 0.4 %

Shares of Novo Nordisk A/S stock opened at $90.94 on Wednesday. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $408.07 billion, a price-to-earnings ratio of 27.64, a PEG ratio of 0.90 and a beta of 0.45. The firm’s 50-day moving average is $85.32 and its two-hundred day moving average is $107.42.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.